Bifogade filer
PDF
Kurs & Likviditet
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Karin Fischer has given notice that she intends to resign as CEO of RLS Global AB (publ). The Board has initiated the search for a new, R&D-focused CEO and Karin Fischer will continue in her role, until a new CEO has been appointed, to ensure a smooth succession.
RLS Global ("RLS") has over the past few years, under Karin Fischer's leadership, transformed into a commercial stage wound care company. The expansion in Europe is well underway through our partnership with ConvaTec, which is responsible for the commercialization of ChloraSolv in these markets. European regulatory approval for ChloraSolv, the company's main product for debridement of hard-to-heal wounds, has been secured and the product is launched in certain European countries. As previously communicated, RLS' strategic focus is on expanding ChloraSolv into new indications and therapeutic areas, such as burns, pressure ulcers and animal care, through clinical trials generating further clinical evidence. The focus is also on expanding into new geographies through the partnership with ConvaTec and/or with other leading companies.
"We are grateful for Karin Fischer's contribution to RLS as CEO, including bringing ChloraSolv to the market and securing a leading, global commercial partner. Karin has also hired a strong management team which is important and makes us well equipped for the next stage in the company's development." says Steve Krognes, Chairman of the Board, RLS.
"It has been a privilege to lead RLS over the past few years, and together with the leadership team successfully bringing ChloraSolv to patients in need. I am personally convinced that ChloraSolv will lead to significant patient benefits in the years to come as the full potential of this product is realized," says Karin Fischer, CEO, RLS.
"We are now entering a new phase for RLS, with focus on accelerating the global expansion of ChloraSolv and realizing the full potential of our unique buffered hypoclorite platform. This means, among other things, establishing reimbursement and sales of ChloraSolv throughout Europe, and securing further regulatory approvals in new markets such as the US. It also means a broadening of the medical indications through clinical studies and investigating the potential of ChloraSolv in animal care.
To succeed in this, we intend to hire a CEO with broad regulatory and R&D expertise, as well as managing strategic partnerships and international expansion. Karin Fischer, who has been CEO of RLS since August 2018, will continue in her role and ensure a smooth leadership transition until the right successor has been appointed," concludes Steve Krognes.
TRADING PLACE AND CERTIFIED ADVISER
RLS Global's shares have been listed on the Nasdaq First North Growth Market since 17[th] May, 2017 and trading takes place under the short name RLS. Certified Adviser is Redeye Aktiebolag, phone: +46 8 121 576 90, email: certifiedadviser@redeye.se.During the period 2012-2017, the company was listed on Aktietorget.
RLS Global (publ) is obliged to make the information contained herein public pursuant to the EU market abuse regulation (MAR). The information was submitted for publication through the agency of the above contact person, 04-04-2022 08:55 CET.